title: Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease.
abstract: BACKGROUND
  Infliximab is used in the treatment of inflammatory bowel disease. Previously reported neurological complications include central and peripheral demyelinating disorders and neuropathies occurring months into therapy.
  
  
  METHODS
  A seven-year-old boy diagnosed with ulcerative colitis and primary sclerosing cholangitis received infliximab. Six hours following his uneventful infusion, he awoke with headache and emesis and rapidly became obtunded. Neurological examination revealed minimally reactive pupils and otherwise absent brainstem reflexes. Cranial computed tomography revealed hypodense lesions in the cerebral hemispheres, cerebellum, and pons accompanied by hemorrhage. Magnetic resonance imaging showed diffusion restriction concerning for ischemia with areas of ring enhancement suggestive of inflammation. Vessel imaging was normal, and cerebrospinal fluid and serum studies showed only an extremely elevated level of d-dimer. Echocardiogram showed depressed ventricular function but neither intracardiac shunt nor thrombus. Within four days he met criteria for brain death. Autopsy was refused.
  
  
  CONCLUSIONS
  This is the first report of a fulminant, fatal central nervous system process to occur after an initial dose of infliximab. The differential diagnosis includes multifocal arterial strokes and a devastating demyelinating process.
authors.affiliation: Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: fbaumer@stanford.edu.
authors.forename: Fiona M
authors.initials: FM
authors.lastname: Baumer
authors.affiliation: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
authors.forename: Jodie
authors.initials: J
authors.lastname: Ouahed
authors.affiliation: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
authors.forename: Menno
authors.initials: M
authors.lastname: Verhave
authors.affiliation: Department of Neurology, Boston Children's Hospital, Boston, Massachusetts; Department of Psychiatry, Boston Children's Hospital, Boston, Massachusetts; Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rivkin
mesh_terms: D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000401:mortality*; D002648:Child; D017809:Fatal Outcome; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008297:Male
chemical_list: D000069285:Infliximab
keywords: AHLE; acute hemorrhagic leukoencephalitis; demyelinating disease; inflammatory bowel disease; infliximab; ischemic stroke; primary sclerosing cholangitis; ulcerative colitis